← Leaderboards
Catherine Qing Sun
University Of California, San Francisco
$1,764,318
Attributed
$1,764,318
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $747.4K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,764,318 · 2
By mechanism
K23$1,272,889 · 1
R34$491,429 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- David Antonetti$16,933,384
- Gregory M Marcus$14,919,010
- Jeremy David Keenan$19,787,326
- Thomas Hoffmann$1,646,620
- Alka M Kanaya$23,487,726
Others in their field
Other Emerging Leaders on “Race”
- Chanza Baytop · Westat, Inc.$271,217,917
- Abraham Aizer Brody · New York University School Of Medicine$16,749,445
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$14,031,836
- Michael P Harms · Washington University$13,645,932
- Leigh A Johnson · University Of North Texas Hlth Sci Ctr$12,505,706
- Bjorn E Oskarsson · Mayo Clinic Jacksonville$11,846,278
Research focus
RaceVisionInfrastructurePublishingStructureUnited StatesFollow-UpHealth InsuranceParticipantPrimary OutcomeRegistriesBlindnessTreatment As UsualCaringElectronic Health RecordEthnic OriginFoundationsFutureClinical ResearchOphthalmologyPatient RecruitmentsPharmaceutical PreparationsDesignCalifornia
Grant awards (6)
Real-world outcomes of proliferative diabetic retinopathy$256,003
K23 · FY2025 · EY · contact PI
Designing a Pragmatic Registry-based Randomized Controlled Trial for Open-Angle Glaucoma Treatment in the US$491,429
R34 · FY2024 · EY · contact PI
Real-world outcomes of proliferative diabetic retinopathy$256,003
K23 · FY2024 · EY · contact PI
Real-world outcomes of proliferative diabetic retinopathy$256,003
K23 · FY2023 · EY · contact PI
Real-world outcomes of proliferative diabetic retinopathy$252,644
K23 · FY2022 · EY · contact PI
Real-world outcomes of proliferative diabetic retinopathy$252,236
K23 · FY2021 · EY · contact PI